Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:21:57 2024-04-19 pm EDT 5-day change 1st Jan Change
13.1 USD +0.54% Intraday chart for Sage Therapeutics, Inc. -14.99% -39.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
TD Cowen Cuts Sage Therapeutics Price Target to $16 From $30, Maintains Buy Rating MT
Scotiabank Cuts Price Target on Sage Therapeutics to $19 From $34, Maintains Sector Outperform Rating MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $17 From $25, Maintains Perform Rating MT
Top Midday Decliners MT
BofA Securities Downgrades Sage Therapeutics to Underperform From Neutral, Adjusts Price Target to $14 From $24 MT
Sector Update: Health Care Stocks Advance Premarket Wednesday MT
Sector Update: Health Care MT
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday MT
Transcript : Sage Therapeutics, Inc. - Special Call
Top Premarket Decliners MT
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint MT
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease CI
JPMorgan Raises Price Target on Sage Therapeutics to $29 From $24, Maintains Overweight Rating MT
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board CI
Deutsche Bank Adjust Sage Therapeutics Price Target to $18 From $21, Maintains Hold Rating MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $25 From $23, Maintains Perform Rating MT
RBC Raises PT on Sage Therapeutics to $26 From $21, Says Early Metrics From Zurzuvae Launch Suggest Promising Signs; Keeps Sector Perform, Speculative Risk MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday MT
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines MT
Transcript : Sage Therapeutics, Inc., Q4 2023 Earnings Call, Feb 14, 2024
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (SAGE) SAGE THERAPEUTICS Posts Q4 Revenue $78M, vs. Street Est of $61M MT
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Wedbush Adjusts Sage Therapeutics' Price Target to $24 From $22, Keeps Neutral Rating MT
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC CI
Chart Sage Therapeutics, Inc.
More charts
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
13.04 USD
Average target price
24.39 USD
Spread / Average Target
+87.10%
Consensus
  1. Stock Market
  2. Equities
  3. SAGE Stock
  4. News Sage Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Edge Higher Premarket Wednesday